SOUTH SAN FRANCISCO,
Calif., Dec. 11, 2024 /PRNewswire/ -- IDEAYA
Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology
company committed to the discovery and development of targeted
therapeutics, announced agenda topics for its virtual Investor
R&D Day. The webcast event will be hosted by IDEAYA on
Monday, December 16, 2024 at
8:00 am to 9:30 am ET.
The presentations by IDEAYA management and key
opinion leaders will showcase scientific insights and clinical
development opportunities across IDEAYA's precision medicine
oncology pipeline. In addition, IDEAYA will highlight its
next-generation precision medicine pipeline programs, including
IDE275 / GSK959, a potential first-in-class and best-in-class Phase
1 Werner Helicase inhibitor, IDE892, a potential best-in-class
MTA-cooperative PMRT5 inhibitor, IDE034, a potential first-in-class
B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate
(BsADC), and a potential first-in-class lysine acetyltransferase
6/7 (KAT6/7) development candidate.
The IDEAYA Investor R&D Day Webcast agenda
will be the following:
Agenda Topics
- Building Global Leader in Precision Medicine Oncology
- Uveal Melanoma Roundtable
- Treatment Paradigms in Neoadjuvant Uveal Melanoma
- New Paradigms to Address Tumor Heterogeneity and Drug
Resistance
- Mechanistic Rationale Underpinning IDE161/Keytruda and
IDE161/ADC Combination Opportunities
- IDEAYA and GSK Partnership
- IDE275 / GSK959 (Phase 1) Werner Helicase Program Update
by GSK
- Development Candidate Updates
- IDE892 (PRMT5), IDE034 (B7H3/PTK7 Bispecific Topo ADC),
and KAT6/7 Development Candidates
R&D Day Guest Speakers
- Carol Shields, M.D., Chief,
Ocular Oncology Service at Wills Eye Hospital and Professor of
Ophthalmology at Thomas Jefferson
University
- Amy Schefler, M.D., Partner at Retina Consultants of
Texas, and Clinical Associate
Professor at Weill Cornell Medical College, Houston Methodist
Hospital and University of Texas Health
Science Center at Houston
- Kornelia Polyak, M.D., Ph.D.,
Professor of Medicine at Dana-Farber Cancer Institute (DFCI),
Harvard Medical School, a co-leader of
the Cancer Cell Biology Program at the Dana-Farber Harvard Cancer
Center, and a member of the National Academy of Sciences and the
National Academy of Medicine
- Timothy Yap, MBBS, Ph.D., Professor, Department for
Investigational Cancer Therapeutics and Department of Thoracic/Head
and Neck Medical Oncology, Medical Director, Institute for Applied
Cancer Science, Associate Director of Translational Research,
Khalifa Institute for Personalized
Cancer Therapy, M.D. Anderson Cancer Center
- Ramon Kemp, Ph.D., Vice President, Head, Oncology EDL,
GSK
Investor R&D Day Webcast Presentation and
Registration Information
IDEAYA's Investor R&D Day webcast
presentation will be available on the company's website, at its
Investor Relations portal (https://ir.ideayabio.com/) in advance of
the investor webcast presentation at approximately 6:00 am ET.
Registration is available at
https://ir.ideayabio.com/events or
https://lifescievents.com/event/ideaya-4/.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company
committed to the discovery and development of targeted therapeutics
for patient populations selected using molecular diagnostics.
IDEAYA's approach integrates capabilities in identifying and
validating translational biomarkers with drug discovery to select
patient populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug discovery
capabilities to synthetic lethality – which represents an emerging
class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking
statements, including, but not limited to, (i) statements related
to participation in, presentation at, and/or content of IDEAYA's
Investor R&D Day (ii) clinical development opportunities across
IDEAYA's precision medicine oncology pipeline; and (iii) the
potential therapeutic opportunities of IDEAYA's pipeline programs,
including treatment for uveal melanoma, new paradigms to
address tumor heterogeneity and drug resistance, the
IDE161/Keytruda and IDE161/ADC combinations, and the IDE275 /
GSK959 (Werner Helicase Program); and IDE892 (a MTA-cooperative
PMRT5 inhibitor), IDE034 (a B7H3/PTK7 topo-I-payload bispecific
antibody drug conjugate (BsADC), and a lysine acetyltransferase 6/7
(KAT 6/7) development candidates. IDEAYA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of IDEAYA in
general, see IDEAYA's Quarterly Report on Form 10-K filed on
February 20, 2024 and any current and
periodic reports filed with the U.S. Securities and Exchange
Commission.
Investor and Media Contact
IDEAYA
Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-agenda-for-investor-rd-day-webcast-on-december-16-2024-302328702.html
SOURCE IDEAYA Biosciences, Inc.